Organisation paid for research Program year 2025 Source: CMS Open Payments

The Lung Research Center LLC

Neither a doctor nor a teaching hospital

Research payments

$1,510,015

438 payments

Through program year 2025, The Lung Research Center LLC is reported as receiving $1,510,015 in research payments, across 438 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $220,110 85
2024 Research $350,117 105
2023 Research $243,980 86
2022 Research $447,848 84
2021 Research $89,998 22
2020 Research $51,114 8
2019 Research $106,849 48

Breakdown

Who paid Research payments · program years 2019–2025
  1. United Therapeutics Corporation $457,307 167 payments
  2. Roche Products Limited $434,508 50 payments
  3. Genentech, Inc. $154,651 50 payments
  4. GlaxoSmithKline, LLC. $147,356 53 payments
  5. AstraZeneca Pharmaceuticals LP $119,972 11 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $55,176 5 payments
  7. Chiesi USA, Inc. $44,345 11 payments
  8. Regeneron Pharmaceuticals, Inc. $25,558 3 payments
  9. Insmed, Inc. $20,497 50 payments
  10. Hoffmann-La Roche Limited $17,679 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. Trial to Evaluate the Efficacy and Safety of PRM 151 in Patients With Idiopathic Pulmonary Fibrosis $335,570 35 payments
  2. A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis $284,878 82 payments
  3. PH Iib of Astegolimab in COPD $138,026 42 payments
  4. An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis $124,750 58 payments
  5. A 52-Week, Randomised, Double-Blind, Double-Dummy, Parallel Group, Mul $120,751 44 payments
  6. PH III Ole Trial to Evaluate Long Term Safety and Efficacy of PRM 151 in Patients With Ipf $98,938 15 payments
  7. A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) $62,455 2 payments
  8. A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) $35,263 14 payments
  9. Nintedanib PF ILD $34,764 2 payments
  10. Ph III OLE of Astegolimab in COPD $33,357 11 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record